Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $25.31 million. The enterprise value is $17.99 million.
| Market Cap | 25.31M |
| Enterprise Value | 17.99M |
Important Dates
The last earnings date was Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 12.78 million shares outstanding. The number of shares has increased by 6.00% in one year.
| Current Share Class | 12.78M |
| Shares Outstanding | 12.78M |
| Shares Change (YoY) | +6.00% |
| Shares Change (QoQ) | +10.40% |
| Owned by Insiders (%) | 4.83% |
| Owned by Institutions (%) | 18.49% |
| Float | 9.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96
| Current Ratio | 1.96 |
| Quick Ratio | 1.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -400.92% and return on invested capital (ROIC) is -203.72%.
| Return on Equity (ROE) | -400.92% |
| Return on Assets (ROA) | -74.29% |
| Return on Invested Capital (ROIC) | -203.72% |
| Return on Capital Employed (ROCE) | -361.37% |
| Weighted Average Cost of Capital (WACC) | 17.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.74% in the last 52 weeks. The beta is 2.33, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.33 |
| 52-Week Price Change | -50.74% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 26.09 |
| Average Volume (20 Days) | 119,787 |
Short Selling Information
The latest short interest is 693,034, so 5.42% of the outstanding shares have been sold short.
| Short Interest | 693,034 |
| Short Previous Month | 846,372 |
| Short % of Shares Out | 5.42% |
| Short % of Float | 7.04% |
| Short Ratio (days to cover) | 7.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.47M |
| Pretax Income | -18.65M |
| Net Income | -18.65M |
| EBITDA | -15.45M |
| EBIT | -15.47M |
| Earnings Per Share (EPS) | -$1.63 |
Balance Sheet
The company has $7.36 million in cash and $39,715 in debt, with a net cash position of $7.32 million or $0.57 per share.
| Cash & Cash Equivalents | 7.36M |
| Total Debt | 39,715 |
| Net Cash | 7.32M |
| Net Cash Per Share | $0.57 |
| Equity (Book Value) | -3.22M |
| Book Value Per Share | -0.25 |
| Working Capital | 4.14M |
Cash Flow
In the last 12 months, operating cash flow was -$14.08 million and capital expenditures -$556, giving a free cash flow of -$14.08 million.
| Operating Cash Flow | -14.08M |
| Capital Expenditures | -556 |
| Depreciation & Amortization | 15,809 |
| Net Borrowing | n/a |
| Free Cash Flow | -14.08M |
| FCF Per Share | -$1.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lantern Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.00% |
| Shareholder Yield | -6.00% |
| Earnings Yield | -72.23% |
| FCF Yield | -54.52% |
Analyst Forecast
The average price target for Lantern Pharma is $17.50, which is 783.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.50 |
| Price Target Difference | 783.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |